Taconic Biosciences releases COVID-19 mouse model

By The Science Advisory Board staff writers

April 29, 2021 -- Taconic Biosciences announced it has developed a human angiotensin-converting enzyme 2 (hACE2) AC22 lethality-resistant transgenic mouse model that will permit the study of sublethal COVID-19 infection.

Taconic launched its first hACE2 model in October 2020. The mouse experiences a lethal response to infection by SARS-CoV-2. Conversely, the new AC22 mouse is lethality-resistant when infected, which will enable therapeutic, vaccine, and postinfection symptom research, the company stated.

Study-ready cohorts of animals are available for immediate ordering, Taconic reported.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.